(Q51630276)

8 April 2018

title

Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. (English)

1 reference

8 April 2018

1 reference

Wei Xu

1

1 reference

8 April 2018

Yan Shen

2

1 reference

8 April 2018

Zhenggang Jiang

3

1 reference

8 April 2018

Ying Wang

4

1 reference

8 April 2018

Yiwei Chu

5

1 reference

8 April 2018

Sidong Xiong

6

1 reference

8 April 2018

language of work or name

English

0 references

publication date

1 September 2004

1 reference

8 April 2018

published in

Vaccine

1 reference

8 April 2018

volume

22

1 reference

8 April 2018

issue

27-28

1 reference

8 April 2018

page(s)

3603-3612

1 reference

8 April 2018

The group B coxsackieviruses and myocarditis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B coxsackieviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Expression of coxsackievirus B3 capsid proteins in Escherichia coli and generation of virus-specific antisera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Induction of immune responses by DNA vaccines in large animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan and its derivatives as intestinal absorption enhancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Polysaccharide colloidal particles as delivery systems for macromolecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Strategies for designing and optimizing new generation vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan and its derivatives in mucosal drug and vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan for mucosal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan: some pharmaceutical and biological aspects--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Immune stimulating activity of two new chitosan containing adjuvant formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Effect of chitosan implantation on activation of canine macrophages and polymorphonuclear cells after surgical stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

New generation of mucosal adjuvants for the induction of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Manipulating the immune system: humoral versus cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan as a novel nasal delivery system for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

inferred from DOI database lookup

7 January 2021

based on heuristic

Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.033

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.03.033

1 reference

8 April 2018

PubMed ID

15315839

1 reference

8 April 2018